Literature DB >> 8865407

Substance P-like immunoreactive substance in bronchoalveolar lavage fluids from patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis.

M Takeyama1, S Nagai, K Mori, K Ikawa, N Satake, T Izumi.   

Abstract

In order to find out whether substance P (SP) participates in the inflammatory and fibrotic processes of interstitial lung diseases or not, SP-like immunoreactive substance (SP-IS) concentrations in bronchoalveolar lavage (BAL) fluids from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis were measured using enzyme immunoassay (EIA). The mean SP-IS concentrations in BAL fluids from healthy nonsmokers and healthy smokers were 0.87 +/- 0.19 and 0.98 +/- 0.23 pg/ml, respectively. The mean SP-IS concentration in BAL fluids from patients with IPF was 1.15 +/- 0.39 pg/ml. The value of patients with IPF was significantly higher than that of healthy nonsmokers (p < 0.01). The mean SP-IS concentrations in BAL fluids from pulmonary sarcoidosis patients in stage I, stage II and stage III were 0.91 +/- 0.19, 0.96 +/- 0.35 and 1.00 +/- 0.29 pg/ml, respectively. No correlation was found between SP-IS concentration and pulmonary functions in IPF and sarcoidosis patients. The present results indicate that SP may be involved in the inflammatory process in IPF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8865407     DOI: 10.1007/bf00383966

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  4 in total

Review 1.  Neuroinflammatory Mechanisms of Connective Tissue Fibrosis: Targeting Neurogenic and Mast Cell Contributions.

Authors:  Michael J Monument; David A Hart; Paul T Salo; A Dean Befus; Kevin A Hildebrand
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

2.  The mast cell stabilizer ketotifen fumarate lessens contracture severity and myofibroblast hyperplasia: a study of a rabbit model of posttraumatic joint contractures.

Authors:  Michael J Monument; David A Hart; A Dean Befus; Paul T Salo; Mei Zhang; Kevin A Hildebrand
Journal:  J Bone Joint Surg Am       Date:  2010-06       Impact factor: 5.284

3.  Neurokinin A is the predominant tachykinin in human bronchoalveolar lavage fluid in normal and asthmatic subjects.

Authors:  L G Heaney; L J Cross; L P McGarvey; K D Buchanan; M Ennis; C Shaw
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

4.  Upregulation of neurokinin-1 receptor expression in the lungs of patients with sarcoidosis.

Authors:  Terence M O'Connor; Joseph O'Connell; Darren I O'Brien; Michael W Bennett; Triona Goode; Louise Burke; Charles P Bredin; Fergus Shanahan
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.